JPMorgan raised the firm’s price target on Novo Nordisk to DKK 1,050 from DKK 950 and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- MHRA says evidence doesn’t support link between GLP-1s and suicidal thoughts
- Health apps temporarily profiting from copycat weight-loss drugs, FT says
- Jefferies healthcare analysts hold an analyst/industry conference call
- Novo Nordisk Executives Buy Company Shares
- Statement from President Biden on anti-obesity medications pricing